LEGION CONSO(02129) Issues Profit Warning, Expected pre-tax loss for fiscal year 2025 not less than 5.1 million Singapore dollars, turning from profit to loss year-on-year.
LEGION CONSO (02129) announced that it is expected to incur a pre-tax loss of not less than 5.1 million Singapore dollars in the 2025 fiscal year, while it achieved a pre-tax profit of approximately 5.9 million Singapore dollars in the 2024 fiscal year.
CONSO (02129) announced that it is expected to incur a pre-tax loss of not less than SGD 5.1 million for the fiscal year 2025, while it achieved a pre-tax profit of approximately SGD 5.9 million for the fiscal year 2024.
The announcement stated that the expected loss in fiscal year 2025 is mainly due to: (i) a decrease in revenue from approximately SGD 66.1 million in fiscal year 2024 to approximately SGD 61.2 million in fiscal year 2025. The decrease in revenue is mainly attributed to a decrease in market demand, leading to a significant decrease in sales of truck transportation and freight forwarding services; (ii) an increase in operating costs, including maintenance and logistics-related expenses, leading to a compression of profit margins and impacting profitability; (iii) a decrease in other income, especially a decrease in interest income from fixed deposits and the impact of exchange rate fluctuations; (iv) an increase in operating expenses, including additional professional fees, bank charges, and other administrative costs; and (v) recognition of impairment losses on intangible assets and trade receivables.
Related Articles

CHINARES PHARMA (03320): China Resources Double-Crane Pharmaceutical's net profit attributable to the parent company in 2025 was 1.647 billion yuan, a year-on-year increase of 1.18%.

GIANT BIOGENE (02367) announced its performance in 2025 with a net profit attributable to the parent of approximately 1.915 billion yuan, a decrease of 7.2% year-on-year.

BRII-B(02137) released its annual performance, with a net loss attributable to shareholders of 223 million yuan, a year-on-year decrease of 56.19%.
CHINARES PHARMA (03320): China Resources Double-Crane Pharmaceutical's net profit attributable to the parent company in 2025 was 1.647 billion yuan, a year-on-year increase of 1.18%.

GIANT BIOGENE (02367) announced its performance in 2025 with a net profit attributable to the parent of approximately 1.915 billion yuan, a decrease of 7.2% year-on-year.

BRII-B(02137) released its annual performance, with a net loss attributable to shareholders of 223 million yuan, a year-on-year decrease of 56.19%.

RECOMMEND

“Memory Price Surge” For 100 Days, Low‑End Smartphones Forced Into Decline
19/03/2026

Hong Kong Suddenly Becomes A New Destination For Middle Eastern Capital? Signs Of Increased Allocation Are Evident
19/03/2026

Memory Price Surge Persists For 100 Days, Forcing Low‑End Smartphones Toward Extinction
19/03/2026


